|Articles|July 12, 2023
Are Nitrosamines a Concern for Biologic Manufacturers
Author(s)SGS
This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
3
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
4
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
5
